284 related articles for article (PubMed ID: 27168431)
1. Drug Regulation and Pricing--Can Regulators Influence Affordability?
Eichler HG; Hurts H; Broich K; Rasi G
N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
[No Abstract] [Full Text] [Related]
2. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
3. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
Feldman R; Wang C
N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
[No Abstract] [Full Text] [Related]
4. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
5. Precompetitive research: a new prescription for drug development?
Woodcock J
Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
[No Abstract] [Full Text] [Related]
6. An ethical dilemma. Patents & profits v. access & affordability.
Blasi AE
J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710
[No Abstract] [Full Text] [Related]
7. Pharmaceutical R&D: an age of change?
Baldwin JJ
Future Med Chem; 2014 Jun; 6(10):1109-12. PubMed ID: 25078132
[No Abstract] [Full Text] [Related]
8. An uncertain future for cardiovascular drug development?
Garber AM
N Engl J Med; 2009 Mar; 360(12):1169-71. PubMed ID: 19297568
[No Abstract] [Full Text] [Related]
9. Inadequately met needs.
Nat Biotechnol; 2011 May; 29(5):371. PubMed ID: 21552219
[No Abstract] [Full Text] [Related]
10. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
11. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
12. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
13. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
14. Skies darken over drug companies.
Holmes D
Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103
[No Abstract] [Full Text] [Related]
15. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.
Hakim A; Gupta R; Ross JS
JAMA; 2017 Dec; 318(22):2181-2182. PubMed ID: 29131905
[No Abstract] [Full Text] [Related]
16. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
17. [From a crisis to another...Pharmaceutical industry--economics].
Scheen AJ
Rev Med Liege; 2009 Jan; 64(1):3-5. PubMed ID: 19317093
[No Abstract] [Full Text] [Related]
18. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
19. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
Gunter SJ; Kesselheim AS; Rome BN
JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110
[TBL] [Abstract][Full Text] [Related]
20. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
